[The new face of tuberculosis in the context of the tuberculosis-HIV association in Abidjan, Ivory Coast] NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[The new face of tuberculosis in the context of the tuberculosis-HIV association in Abidjan, Ivory Coast]

Tuber Lung Dis. 1995 Dec;76(6):505-9. Unique Identifier : AIDSLINE MED/96167157
Domoua K; Coulibaly G; N'Dhatz M; Traore F; Kanga K; Konan JB; Beugre LK; Yapi A; Service de pneumophtisiologie, CHU de Treichville, Abidjan, Cote; d'Ivoire.

Abstract: This article reviews the main clinical aspects and progression of HIV-related tuberculosis in Abidjan. HIV prevalence in tuberculosis patients is high, estimated at 46.2% in 1992, with a clear predominance of HIV-1 over HIV-2. More than 61% of co-infected tuberculous patients meet the WHO's clinical definition of AIDS (the Bangui definition) at the time of diagnosis of tuberculosis. This rates falls to 46-51% when cough is excluded from the definition. On X-rays, the signs of pulmonary tuberculosis in co-infected tuberculous patients are atypical in the advanced stages of HIV infection, when extra-pulmonary localization, mainly mediastinal adenopathy, is frequent. Short-course chemotherapy consisting of 2 months' unsupervised daily treatment with rifampicin/isoniazid/pyrazinamide, followed by 4 months of a daily combination of rifampicin/isoniazid, applied in the Ivory Coast since 15 July 1985, has proved successful in HIV-associated tuberculosis, with treatment effectiveness rates of more than 90%.
Keywords: Adult Antitubercular Agents/THERAPEUTIC USE Child Cote d'Ivoire/EPIDEMIOLOGY CD4 Lymphocyte Count Drug Therapy, Combination English Abstract Human HIV Infections/*COMPLICATIONS HIV Seroprevalence HIV-1 HIV-2 Tuberculosis/*COMPLICATIONS/DRUG THERAPY/EPIDEMIOLOGY Tuberculosis, Pulmonary/DIAGNOSIS/RADIOGRAPHY JOURNAL ARTICLE

KWDadultantitubercularagents/therapeuticusechildcoted'ivoire/epidemiologycd4lymphocytecountdrugtherapy,combinationenglishabstracthumanhivinfections/KWDcomplicationshivseroprevalencehiv-1hiv-2tuberculosis/KWDcomplications/drugtherapy/epidemiologytuberculosis,pulmonary/diagnosis/radiographyjournalarticle
960630
M9660723

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .